Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab Plus CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Next Previous
Trial Profile

Rituximab Plus CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Sargramostim; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 14 May 2019 Biomarkers information updated
  • 12 Jul 2013 Planned end date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
  • 16 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top